{"groups":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","id":"FG000","title":"NAC + Neoadjuvant/Adjuvant Pembrolizumab"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","id":"FG001","title":"NAC + Neoadjuvant/Adjuvant Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"141"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"276"},{"groupId":"FG001","numSubjects":"247"}],"type":"Ongoing in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"397"},{"groupId":"FG001","numSubjects":"400"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"396"},{"groupId":"FG001","numSubjects":"399"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"397"},{"groupId":"FG001","numSubjects":"400"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 797 participants that were randomized to trial, 795 received treatment. At the time of the primary analysis data cut-off, 523 participants are ongoing in the study.","recruitmentDetails":"Adult participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC) were recruited to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \\[neoadjuvant phase\\], followed by pembrolizumab alone after surgery \\[adjuvant phase\\]."}